Rajalingam R, Mehra N K, Jain R C, Myneedu V P, Pande J N
Department of Histocompatibility and Immunogenetics, All India Institute of Medical Sciences, New Delhi.
J Infect Dis. 1996 Mar;173(3):669-76. doi: 10.1093/infdis/173.3.669.
HLA antigens were studied by serology and polymerase chain reaction-based sequence-specific oligonucleotide hybridization techniques in 153 patients with pulmonary tuberculosis (PTB) and 289 healthy controls. HLA-DR2 was present more frequently in PTB patients than in controls (51% vs. 36.3%; corrected P[Pc]=.029, relative risk [RR] = 1.8). The DR2 association was stronger in patients in the drug-failure group (n=56; Pc=.000012, RR=3.7) than in healthy controls and in patients in the drug-responder group. No significant deviation was observed in HLA allelic frequencies in various patient groups, as determined by radiographs of lung lesions. Molecular subtyping of DR2 revealed that the bulk of the allele was DRB11501 and DRB11502 in patients and controls. There was no skewing of the frequency of these molecular subtypes of DR2 in patients, suggesting that the whole DR2 molecule or its closely linked gene(s) may be involved in governing patient susceptibility to PTB and, particularly, development of the severe drug-resistant form of the disease.
采用血清学和基于聚合酶链反应的序列特异性寡核苷酸杂交技术,对153例肺结核患者(PTB)和289名健康对照者的HLA抗原进行了研究。HLA - DR2在PTB患者中的出现频率高于对照组(51%对36.3%;校正P[Pc]=0.029,相对风险[RR]=1.8)。在治疗失败组患者(n = 56;Pc = 0.000012,RR = 3.7)中,DR2的关联性强于健康对照组和治疗反应良好组患者。根据肺部病变的X光片判断,各患者组的HLA等位基因频率未观察到显著偏差。DR2的分子亚型分析显示,患者和对照组中该等位基因的大部分为DRB11501和DRB1l502。患者中DR2这些分子亚型的频率无偏差,提示整个DR2分子或其紧密连锁的基因可能参与决定患者对PTB的易感性,尤其是严重耐药形式疾病的发生。